<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Aug. 17, 2020 (HealthDay News) — Age at surgery, education level, and preventive mastectomy are associated with hormone therapy (HT) use after preventive oophorectomy in BRCA<\/i> mutation carriers, according to a study published online Aug. 10 in Menopause<\/i>.<\/p>\n
Javier Mejia-Gomez, M.D., from the University of Toronto, and colleagues identified the frequency and predictors of HT use in BRCA<\/i> mutation carriers who underwent preventive oophorectomy before age 50 years. Participants had a minimum of two years of follow-up and completed questionnaires every two years to provide information on HT use and other important variables.<\/p>\n
Overall, the analyses included 793 women with BRCA1<\/i> or BRCA2<\/i> mutations. The researchers found that oophorectomy occurred at a mean of 42 years. After oophorectomy, 61 percent of women reported using HT. Young age at surgery, a high level of education, and preventive mastectomy were factors associated with HR use.<\/p>\n
“The existing evidence, as well as current management guidelines, indicates that estrogen-containing HT is a reasonable option for high-risk women who have undergone preventive mastectomy as well as surgical menopause,” the authors write. “Additional training in this area may lead to a more personalized approach to managing menopausal symptoms without increasing cancer risk.”<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n